Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A cutaneous necrobiotic disorder characterized by firm, yellow plaques or nodules, often in a periorbital distribution. It is often accompanied by an elevated erythrocyte sedimentation rate; leukopenia; and monoclonal gammopathy (IgG-kappa type) and systemic involvement.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 5:57 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning necrobiotic xanthogranuloma
Updated Aug 4, 2026
Recent research published in PubMed highlights necrobiotic xanthogranuloma, a rare skin condition characterized by yellowish nodules. The study provides insights into its pathophysiology and potential treatment approaches.
A recent study reviews dermoscopic and reflectance confocal microscopic findings in necrobiotic xanthogranuloma (NXG) and discusses treatment options, including intravenous immunoglobulin (IVIG). This research contributes to the understanding of NXG and potential therapeutic approaches.